Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

ALK negative

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

ALK negative	Non Small Cell Lung Cancer	ALK negative	Non Small Cell Lung Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
ALK negative	Mantle Cell Lymphoma	ALK negative	Mantle Cell Lymphoma	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2
ALK negative	Non Small Cell Lung Cancer	ALK negative	Non Small Cell Lung Cancer	pembrolizumab + atezolizumab Sensitive: B - Late Trials pembrolizumab + atezolizumab Sensitive : B	pembrolizumab + atezolizumab Sensitive: B - Late Trials pembrolizumab + atezolizumab Sensitive : B
ALK negative	Non-Hodgkin’s Lymphoma	ALK negative	Non-Hodgkin’s Lymphoma	etoposide IV Sensitive: C3 – Early Trials etoposide IV Sensitive : C3	etoposide IV Sensitive: C3 – Early Trials etoposide IV Sensitive : C3
ALK negative	Non Small Cell Lung Cancer	ALK negative	Non Small Cell Lung Cancer	sintilimab Sensitive: C3 – Early Trials sintilimab Sensitive : C3	sintilimab Sensitive: C3 – Early Trials sintilimab Sensitive : C3